SNU-387Homo sapiens (Human)Cancer cell line

Also known as: NCI-SNU-387, SNU387

🤖 AI SummaryBased on 12 publications

Quick Overview

Human hepatocellular carcinoma cell line with TERT promoter mutations and genomic alterations.

Detailed Summary

SNU-387 is a human hepatocellular carcinoma (HCC) cell line derived from a patient with liver cancer. It is characterized by frequent somatic mutations in the TERT promoter, which is associated with increased telomerase activity and tumor progression. The cell line exhibits genomic instability, including gains and losses of chromosomal regions, such as 1q, 7, 8q, and losses in 4q, 16q, and the Y chromosome. These alterations are linked to the activation of oncogenes and inactivation of tumor suppressor genes, contributing to hepatocarcinogenesis. SNU-387 is used in research to study the molecular mechanisms of HCC and to develop targeted therapies.

Research Applications

Study of TERT promoter mutations in HCCInvestigation of genomic instability in liver cancerDevelopment of targeted therapies for HCC

Key Characteristics

Frequent TERT promoter mutationsGenomic alterations including gains and lossesY chromosome loss
Generated on 6/15/2025

Basic Information

Database IDCVCL_0250
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age41
Age CategoryAdult
SexFemale
Raceasian

Disease Information

DiseaseAdult hepatocellular carcinoma
LineageLiver
SubtypeHepatocellular Carcinoma
OncoTree CodeHCC

DepMap Information

Source TypeATCC
Source IDACH-000478_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Lys164Ter (c.490A>T)Homozygous-from parent cell line SNU-387
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleNRASp.Gln61Lys (c.181C>A)UnspecifiedAcquired during resistance selection processPubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
13,14
D13S317
12
D16S539
9
D18S51
14
D19S433
14
D21S11
31
D2S1338
17,23
D3S1358
16
D5S818
10,12
D7S820
8,10
D8S1179
13,14
FGA
22
Penta D
8
Penta E
16
TH01
7
TPOX
8,9
vWA
14
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Cevik D., Yildiz G., Ozturk M.

World J. Gastroenterol. 21:311-317(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Biology of SNU cell lines.";

Ku J.-L., Park J.-G.

Cancer Res. Treat. 37:1-19(2005).

Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.

Park S.-J., Jeong S.-Y., Kim H.J.

Cancer Genet. Cytogenet. 166:56-64(2006).

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Won Y.-J., Kim S.-T., Park J.-G.

Int. J. Cancer 67:898-902(1996).

Characterization of cell lines established from human hepatocellular carcinoma.

Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Int. J. Cancer 62:276-282(1995).